PFOAS, or forever chemicals, are everywhere nowadays. Exposure is unavoidable, but teens appear especially vulnerable ...

Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

These synthetic compounds — known as per- and polyfluoroalkyl substances, or PFAS — could as much as triple the chances ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Albumin is the most common protein in the blood, a vital molecule produced by the liver that helps maintain fluid balance and ...

Atea continues to advance its global Phase 3 program evaluating the fixed-dose combination (FDC) of BEM, a nucleotide analog ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...

ElevateBio Life Edit (R) is the Company's gene editing technologies and R&D business, focused on building the world's largest gene editing toolbox to expand addressable diseases and open a new ...

A two-meter aluminum sculpture, the base in Vesuvian stone and wise eyes, designed to recall the ability of the great ...

From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...